Glaucoma, Open-AngleFPSPLTTCOAGNCT02679482
Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma
An observational study of Glaucoma, Open-Angle and Glaucoma, Primary Open Angle, run by Fundación Oftalmológica Nacional at 1 site in Colombia.
Trial summary
The purpose of this study is to follow and describe the outcomes of patients after selective and pascal laser trabeculoplasty treatment for chronic open-angle glaucoma. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Glaucoma, Open-Angle, Glaucoma, Primary Open Angle, Exfoliation Glaucoma
- How many people
- 36 participants
- Where
- 1 siteColombia
- Study dates
- Sep 2014to Oct 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with Open-Angle Glaucoma with a non-optimal intraocular pressure control with topical/oral medications, who underwent to laser trabeculoplasty treatment, attending the Fundacion Oftalmológica Nacional between June 2014 and july 2016 on Bogotá-Colombia.
Who may be able to join
- Subjects of either sex, aged ≥ 40 years
- Best distant visual acuity, better than or equal to 20/200
- Diagnosis of primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma, with open angles by Posner lens gonioscopy
- Intraocular pressure ≥ 20 mmHg, with medical treatment, as monotherapy or combination therapy.
- Previous computerized visual field within the six months previous performing trabeculoplasty
- Patients who understand and sign the informed consent
- Patient diagnosed with open-angle glaucoma who will undergo selective laser trabeculoplasty (SLT) with an amplitud of 360 degrees, or laser trabeculaplastia in pattern (PASCAL-Pattern Scan Laser) with an amplitud of 360 degrees. Made at initial session or in two 7 days separate sessions (each with session with an amplitude of180 degrees)
Who cannot join
- Advanced loss on visual field within 10 degrees of central fixation in a previous 3 months visual field
- Previous history of surgery for glaucoma management, except peripheral iridotomy
- Corneal disease that does not allow the use of applanation tonometer nor an accurate measurement of intraocular pressure
- Corneal disease which prevents adequate visualization of trabeculo by gonioscopy lens
- Use of topical or systemic steroids
- Concomitant participation in another study
- Coexistence of other ocular pathology different than cataract.
Trial locations and contacts
1 site in 1 country.
Colombia1 site, 1 recruiting
- Recruiting
Fundacion Oftalmológica Nacional
Bogotá, Bogota D.C., 110231
Sandra Belalcazar, MD
Hector D Forero, MD
About this study
The purpose of this study is to follow and describe the outcomes of patients after selective and pascal laser trabeculoplasty treatment for chronic open-angle glaucoma.
Read the detailed description
Selective laser trabeculoplasty (SLT) and pattern laser trabeculoplasty (PLT, a novel computer-guided laser that is being using to treat open-angle glaucoma) are two laser surgery methods to make a trabeculoplasty on patients with open angle glaucoma. An observational prospective study will be performed, a consecutive convenience sample patients with indication for SLT or PLT will be recruited during June 2014 to uly 2016 and follow-up until 6 months, at the Fundación Oftalmológica Nacional (Bogotá-Colombia). A non-probabilistic convenience sampling is performed, considering that the average number of patients diagnosed with chronic open-angle glaucoma undergoing to Laser trabeculoplasty at the Oftalmológica Nacional Fundacion corresponds to approximate 2 per month. Therefore it is expected to enroll one patient per month for each of the laser used (SLT and PLT) for trabeculoplasty. Finally obtaining a sample size of 18 patients per type of laser for a total of 36 patients in the recruitment period, between September 2014 and July 2016.
This study is strictly observational, that's why the laser procedure is covered by the national health insurance of each patient, as well the complications due to the same procedure. An evaluation pre trabeculoplasty and a consecutive 5 visits will be perform as follows:
Visit 0 - Pre-procedure visit: the subjects that will undergo laser trabeculoplasty either Selective laser or PASCAL laser will be invited to participate and an informed consent will be carried out. The information concerting to demographics characteristics (study eye, age, gender and ethnicity), clinical characteristics (date of glaucoma diagnosis, number of medications used to treat glaucoma, time of use of actually anti-glaucomatous topical medication) and slit lamp and ophthalmoscopy examination (corneal aspect, iris color, pupil gonioscopy, intraocular pressure, lens status, vitreous cells, vertical C/D ratio, optic nerve edge, rim characteristic [ISNT pattern], peripapilar atrophy, state of fovea, state of peripheral retina and state of choroid for both eyes) will be extracted and recorded on respective case report form (CRF). The data will be scored according to the grading criteria outlined below:
Study eye: the eye under the follow-up 0 - Right eye 1 - Left eye
Geder: the state of being male or female 0 - Male 1 - Female
Ethnicity: the fact or state of belonging to a social group that has a common national or cultural tradition.
0 - Hispanic
- - Black
- - White
- - Asian
Number of medications used: anti-glaucoma medication used by the patient 0 - 0
- - 1
- - 2
- - 3
- - 4
Corneal aspect: state in which the cornea is at baseline 0 - Normal 1 - Anormal
Iris color: iris pigmentation 0 - Light
- - Medium
- - Dark
Gonioscopy (Shaffer classification): amplitude of irido-corneal angle maseure by poster lens and noted by the Shaffer scale on each quadrant superior, nasal, temporal and inferor angle 0 - 0
- - 1
- - 2
- - 3
- - 4
Intraocular pressure: pressure inside the eye measured in millimeters of mercury Value in mmhg, measure with Goldman tonometer
Lens status: clouding of the lens Nuclear, Subcapsular and Cortical 0 - 0
- - 1
- - 2
- - 3
- - 4
Vitreous cells: number of cells per milimeter in the vitreous cavity 0 - 0 1 - traces 2 - +1 3 - +2 4 - +3 5 - +4
Vertical C/D ratio: relation between cup and optic nerve disc 0 - 0.1
- - 0.2
- - 0.3
- - 0.4
- - 0.5
- - 0.6
- - 0.7
- - 0.8
- - 0.9
- - 1.0
Optic nerve edge: regularly over the optic disc 0 - Regular
1 - Irregular
Rim characteristic [ISNT pattern]: reduction pattern in the thickness of neural ring 0 - Conserved 1 - Not conserved
Peripapilar atrophy: presence of atrophy over the disc 0 - Alfa
1 - Beta 3 - Not apply
State of fovea: normality of the fovea 0 - normal
1 - abnormal
State of peripheral retina: state of the peripheral retina 0 - normal
1 - abnormal
State of choroid: choroidal health 0 - normal
1 - abnormal
After the visit 0, a 5 consecutive visits will be performed: for 1 day, 1 week, 1 month, 3 months and 6 months after the procedure. Identical data will be extracted, ophthalmological examination data, slit lamp exam, and the computerized visual fields (CVF) (CVF only at 3 and 6 months).
One member of the investigation team will collect all information during the follow-up time, and a second one member will review and collate data.
Statistical analysis will be performed in SPSS version 21. Univariate analyzes will perform; for categorical variables, frequency distribution will be made and reported in percentage, for the quantitative variables a measure of central tendency and dispersion will be made (mean, standard deviation and range) will calculate according to the relevance for each variable analyzed. Demographics such as age and gender variables will be described. For bivariate analysis comparing polytomous qualitative and quantitative variables (evolution of intraocular pressure with the type of trabeculoplasty used, number of antihypertensive medications required after the procedure with the type of trabeculoplasty, quantification of cellularity in the anterior chamber with type of trabeculoplasty) using parametric statistical analysis with ANOVA for independent samples and nonparametric with Kruskal-Wallis test. Also comparison of quantitative variables with quantitative variables (intraocular pressure before treatment and evolution of intraocular pressure after treatment) will be performed using the parametric inferential statistical Pearson correlation analysis and for nonparametric a Spearman correlation will be made. Finally, compare qualitative variables with qualitative variables (presence of peak intraocular pressure with type of laser trabeculoplasty performed) using the non-parametric statistical analysis Chi square test, Fisher exact test and Mac Nemar will make.
- Conditions
- Glaucoma, Open-Angle, Glaucoma, Primary Open Angle, Exfoliation Glaucoma, Glaucoma, Pigmentary
- Keywords
- Primary Open Angle Glaucoma, Selective Laser Trabeculoplasty, Pattern Scan Laser Trabeculoplasty
- Medical subject headings
- Glaucoma, Open-Angle, Exfoliation Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Selective laser trabeculoplasty (SLT) | Patients who underwent to Selective laser trabeculoplasty | |
| Pattern laser trabeculoplasty (PLT) | Patients who underwent to Pattern laser trabeculoplasty |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intraocular pressure
The eye pressure measured in millimeters of mercury, measure with Goldman tonometer at follow-up period
Measured: Six months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2016 (estimated)
- Study startSep 2014
- Primary completionSep 2016 (estimated)
- Study completionOct 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (18)Papers the sponsor has linked to this study.
- Other trials for Glaucoma, Open-AngleStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundación Oftalmológica Nacional
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sandra Belalcazar, MD, Principal investigator, Fundacion Oftalmológica Nacional
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02679482
- Sponsor's protocol ID
- FONCI6001
- Acronym
- FPSPLTTCOAG
- Status last verified
- Feb 2016
- First submitted
- 6 Feb 2016
- Last updated
- 17 Feb 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Publications
Wang W, He M, Zhou M, Zhang X. Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis. PLoS One. 2013 Dec 19;8(12):e84270. doi: 10.1371/journal.pone.0084270. eCollection 2013.
PubMed 24367649Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol. 1979 Feb;97(2):319-22. doi: 10.1001/archopht.1979.01020010165017. No abstract available.
PubMed 575877Barkana Y, Belkin M. Selective laser trabeculoplasty. Surv Ophthalmol. 2007 Nov-Dec;52(6):634-54. doi: 10.1016/j.survophthal.2007.08.014.
PubMed 18029271Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995 Apr;60(4):359-71. doi: 10.1016/s0014-4835(05)80093-4.
PubMed 7789416Sanghvi C, McLauchlan R, Delgado C, Young L, Charles SJ, Marcellino G, Stanga PE. Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures. Br J Ophthalmol. 2008 Aug;92(8):1061-4. doi: 10.1136/bjo.2008.139568. Epub 2008 Jun 27.
PubMed 18586905Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014 Jan;5(1):30-43. doi: 10.1177/2040622313511286.
PubMed 24381726Buys YM. Economics of selective laser trabeculoplasty as primary therapy for glaucoma. Can J Ophthalmol. 2006 Aug;41(4):419-20. doi: 10.1016/S0008-4182(06)80001-3. No abstract available.
PubMed 16883356Quigley HA. Glaucoma. Lancet. 2011 Apr 16;377(9774):1367-77. doi: 10.1016/S0140-6736(10)61423-7. Epub 2011 Mar 30.
PubMed 21453963Samples JR, Singh K, Lin SC, Francis BA, Hodapp E, Jampel HD, Smith SD. Laser trabeculoplasty for open-angle glaucoma: a report by the american academy of ophthalmology. Ophthalmology. 2011 Nov;118(11):2296-302. doi: 10.1016/j.ophtha.2011.04.037. Epub 2011 Aug 17.
PubMed 21849211Krasnov MM. [Laser puncture of the anterior chamber angle in glaucoma (a preliminary report)]. Vestn Oftalmol. 1972;3:27-31. No abstract available. Russian.
PubMed 5078295Van Buskirk EM, Pond V, Rosenquist RC, Acott TS. Argon laser trabeculoplasty. Studies of mechanism of action. Ophthalmology. 1984 Sep;91(9):1005-10. doi: 10.1016/s0161-6420(84)34197-5.
PubMed 6493712Alvarado JA, Alvarado RG, Yeh RF, Franse-Carman L, Marcellino GR, Brownstein MJ. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells. Br J Ophthalmol. 2005 Nov;89(11):1500-5. doi: 10.1136/bjo.2005.081307.
PubMed 16234461Bradley JM, Anderssohn AM, Colvis CM, Parshley DE, Zhu XH, Ruddat MS, Samples JR, Acott TS. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalpha. Invest Ophthalmol Vis Sci. 2000 Feb;41(2):422-30.
PubMed 10670472The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology. 1990 Nov;97(11):1403-13.
PubMed 2255512Bylsma SS, Samples JR, Acott TS, Van Buskirk EM. Trabecular cell division after argon laser trabeculoplasty. Arch Ophthalmol. 1988 Apr;106(4):544-7. doi: 10.1001/archopht.1988.01060130590044.
PubMed 3355425
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma
- ClinicalTrials.gov ID
- NCT02679482
- Acronym / sponsor ID
- FPSPLTTCOAG / FONCI6001
- Conditions
- Glaucoma, Open-Angle, Glaucoma, Primary Open Angle, Exfoliation Glaucoma, Glaucoma, Pigmentary
- Keywords
- Primary Open Angle Glaucoma, Selective Laser Trabeculoplasty, Pattern Scan Laser Trabeculoplasty
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Fundación Oftalmológica NacionalUniversity, hospital or other
- Study start
- Sep 2014
- Primary completion
- Sep 2016 (estimated)
- Study completion
- Oct 2016 (estimated)
- First posted
- 10 Feb 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to follow and describe the outcomes of patients after selective and pascal laser trabeculoplasty treatment for chronic open-angle glaucoma.
Detailed description
Selective laser trabeculoplasty (SLT) and pattern laser trabeculoplasty (PLT, a novel computer-guided laser that is being using to treat open-angle glaucoma) are two laser surgery methods to make a trabeculoplasty on patients with open angle glaucoma. An observational prospective study will be performed, a consecutive convenience sample patients with indication for SLT or PLT will be recruited during June 2014 to uly 2016 and follow-up until 6 months, at the Fundación Oftalmológica Nacional (Bogotá-Colombia). A non-probabilistic convenience sampling is performed, considering that the average number of patients diagnosed with chronic open-angle glaucoma undergoing to Laser trabeculoplasty at the Oftalmológica Nacional Fundacion corresponds to approximate 2 per month. Therefore it is expected to enroll one patient per month for each of the laser used (SLT and PLT) for trabeculoplasty. Finally obtaining a sample size of 18 patients per type of laser for a total of 36 patients in the recruitment period, between September 2014 and July 2016.
This study is strictly observational, that's why the laser procedure is covered by the national health insurance of each patient, as well the complications due to the same procedure. An evaluation pre trabeculoplasty and a consecutive 5 visits will be perform as follows:
Visit 0 - Pre-procedure visit: the subjects that will undergo laser trabeculoplasty either Selective laser or PASCAL laser will be invited to participate and an informed consent will be carried out. The information concerting to demographics characteristics (study eye, age, gender and ethnicity), clinical characteristics (date of glaucoma diagnosis, number of medications used to treat glaucoma, time of use of actually anti-glaucomatous topical medication) and slit lamp and ophthalmoscopy examination (corneal aspect, iris color, pupil gonioscopy, intraocular pressure, lens status, vitreous cells, vertical C/D ratio, optic nerve edge, rim characteristic [ISNT pattern], peripapilar atrophy, state of fovea, state of peripheral retina and state of choroid for both eyes) will be extracted and recorded on respective case report form (CRF). The data will be scored according to the grading criteria outlined below:
Study eye: the eye under the follow-up 0 - Right eye 1 - Left eye
Geder: the state of being male or female 0 - Male 1 - Female
Ethnicity: the fact or state of belonging to a social group that has a common national or cultural tradition.
0 - Hispanic
- - Black
- - White
- - Asian
Number of medications used: anti-glaucoma medication used by the patient 0 - 0
- - 1
- - 2
- - 3
- - 4
Corneal aspect: state in which the cornea is at baseline 0 - Normal 1 - Anormal
Iris color: iris pigmentation 0 - Light
- - Medium
- - Dark
Gonioscopy (Shaffer classification): amplitude of irido-corneal angle maseure by poster lens and noted by the Shaffer scale on each quadrant superior, nasal, temporal and inferor angle 0 - 0
- - 1
- - 2
- - 3
- - 4
Intraocular pressure: pressure inside the eye measured in millimeters of mercury Value in mmhg, measure with Goldman tonometer
Lens status: clouding of the lens Nuclear, Subcapsular and Cortical 0 - 0
- - 1
- - 2
- - 3
- - 4
Vitreous cells: number of cells per milimeter in the vitreous cavity 0 - 0 1 - traces 2 - +1 3 - +2 4 - +3 5 - +4
Vertical C/D ratio: relation between cup and optic nerve disc 0 - 0.1
- - 0.2
- - 0.3
- - 0.4
- - 0.5
- - 0.6
- - 0.7
- - 0.8
- - 0.9
- - 1.0
Optic nerve edge: regularly over the optic disc 0 - Regular
1 - Irregular
Rim characteristic [ISNT pattern]: reduction pattern in the thickness of neural ring 0 - Conserved 1 - Not conserved
Peripapilar atrophy: presence of atrophy over the disc 0 - Alfa
1 - Beta 3 - Not apply
State of fovea: normality of the fovea 0 - normal
1 - abnormal
State of peripheral retina: state of the peripheral retina 0 - normal
1 - abnormal
State of choroid: choroidal health 0 - normal
1 - abnormal
After the visit 0, a 5 consecutive visits will be performed: for 1 day, 1 week, 1 month, 3 months and 6 months after the procedure. Identical data will be extracted, ophthalmological examination data, slit lamp exam, and the computerized visual fields (CVF) (CVF only at 3 and 6 months).
One member of the investigation team will collect all information during the follow-up time, and a second one member will review and collate data.
Statistical analysis will be performed in SPSS version 21. Univariate analyzes will perform; for categorical variables, frequency distribution will be made and reported in percentage, for the quantitative variables a measure of central tendency and dispersion will be made (mean, standard deviation and range) will calculate according to the relevance for each variable analyzed. Demographics such as age and gender variables will be described. For bivariate analysis comparing polytomous qualitative and quantitative variables (evolution of intraocular pressure with the type of trabeculoplasty used, number of antihypertensive medications required after the procedure with the type of trabeculoplasty, quantification of cellularity in the anterior chamber with type of trabeculoplasty) using parametric statistical analysis with ANOVA for independent samples and nonparametric with Kruskal-Wallis test. Also comparison of quantitative variables with quantitative variables (intraocular pressure before treatment and evolution of intraocular pressure after treatment) will be performed using the parametric inferential statistical Pearson correlation analysis and for nonparametric a Spearman correlation will be made. Finally, compare qualitative variables with qualitative variables (presence of peak intraocular pressure with type of laser trabeculoplasty performed) using the non-parametric statistical analysis Chi square test, Fisher exact test and Mac Nemar will make.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Selective laser trabeculoplasty (SLT) | – | –Patients who underwent to Selective laser trabeculoplasty |
| Pattern laser trabeculoplasty (PLT) | – | –Patients who underwent to Pattern laser trabeculoplasty |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with Open-Angle Glaucoma with a non-optimal intraocular pressure control with topical/oral medications, who underwent to laser trabeculoplasty treatment, attending the Fundacion Oftalmológica Nacional between June 2014 and july 2016 on Bogotá-Colombia.
Key inclusion criteria (7 listed)
- Subjects of either sex, aged ≥ 40 years
- Best distant visual acuity, better than or equal to 20/200
- Diagnosis of primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma, with open angles by Posner lens gonioscopy
- Intraocular pressure ≥ 20 mmHg, with medical treatment, as monotherapy or combination therapy.
- Previous computerized visual field within the six months previous performing trabeculoplasty
Key exclusion criteria (7 listed)
- Advanced loss on visual field within 10 degrees of central fixation in a previous 3 months visual field
- Previous history of surgery for glaucoma management, except peripheral iridotomy
- Corneal disease that does not allow the use of applanation tonometer nor an accurate measurement of intraocular pressure
- Corneal disease which prevents adequate visualization of trabeculo by gonioscopy lens
- Use of topical or systemic steroids
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Intraocular pressure
Time frame: Six months
The eye pressure measured in millimeters of mercury, measure with Goldman tonometer at follow-up period
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2016.
- Background: PubMed 24367649Wang W, He M, Zhou M, Zhang X. Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis. PLoS One. 2013 Dec 19;8(12):e84270. doi: 10.1371/journal.pone.0084270. eCollection 2013.
- Background: PubMed 575877Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol. 1979 Feb;97(2):319-22. doi: 10.1001/archopht.1979.01020010165017. No abstract available.
- Background: PubMed 18029271Barkana Y, Belkin M. Selective laser trabeculoplasty. Surv Ophthalmol. 2007 Nov-Dec;52(6):634-54. doi: 10.1016/j.survophthal.2007.08.014.
- Background: PubMed 7789416Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995 Apr;60(4):359-71. doi: 10.1016/s0014-4835(05)80093-4.
- Background: PubMed 18586905Sanghvi C, McLauchlan R, Delgado C, Young L, Charles SJ, Marcellino G, Stanga PE. Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures. Br J Ophthalmol. 2008 Aug;92(8):1061-4. doi: 10.1136/bjo.2008.139568. Epub 2008 Jun 27.
- Background: PubMed 24381726Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014 Jan;5(1):30-43. doi: 10.1177/2040622313511286.
- Background: PubMed 16883356Buys YM. Economics of selective laser trabeculoplasty as primary therapy for glaucoma. Can J Ophthalmol. 2006 Aug;41(4):419-20. doi: 10.1016/S0008-4182(06)80001-3. No abstract available.
- Background: PubMed 21453963Quigley HA. Glaucoma. Lancet. 2011 Apr 16;377(9774):1367-77. doi: 10.1016/S0140-6736(10)61423-7. Epub 2011 Mar 30.
- Background: PubMed 21849211Samples JR, Singh K, Lin SC, Francis BA, Hodapp E, Jampel HD, Smith SD. Laser trabeculoplasty for open-angle glaucoma: a report by the american academy of ophthalmology. Ophthalmology. 2011 Nov;118(11):2296-302. doi: 10.1016/j.ophtha.2011.04.037. Epub 2011 Aug 17.
- Background: PubMed 5078295Krasnov MM. [Laser puncture of the anterior chamber angle in glaucoma (a preliminary report)]. Vestn Oftalmol. 1972;3:27-31. No abstract available. Russian.
- Background: PubMed 6493712Van Buskirk EM, Pond V, Rosenquist RC, Acott TS. Argon laser trabeculoplasty. Studies of mechanism of action. Ophthalmology. 1984 Sep;91(9):1005-10. doi: 10.1016/s0161-6420(84)34197-5.
- Background: PubMed 16234461Alvarado JA, Alvarado RG, Yeh RF, Franse-Carman L, Marcellino GR, Brownstein MJ. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells. Br J Ophthalmol. 2005 Nov;89(11):1500-5. doi: 10.1136/bjo.2005.081307.
- Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysisLink provided by the sponsor.
- Argon laser therapy for open-angle glaucoma. A pilot studyLink provided by the sponsor.
- Selective laser trabeculoplastyLink provided by the sponsor.
- Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactionsLink provided by the sponsor.
- Initial experience with the Pascal photocoagulator: a pilot study of 75 proceduresLink provided by the sponsor.
- Glaucoma management: relative value and place in therapy of available drug treatmentsLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Glaucoma, Open-Angle
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Recruiting
The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).
Glaucoma Open-Angle Primary, Hypertension
RecruitingPhase 4
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Open Angle Glaucoma (OAG), Glaucoma
RecruitingObservational study
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
Primary Open Angle Glaucoma
Active, not recruitingObservational study
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Primary Open Angle Glaucoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sandra Belalcazar, MD principal investigator
Fundacion Oftalmológica Nacional
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glaucoma, Open-Angle and Glaucoma, Primary Open Angle, run by Fundación Oftalmológica Nacional at 1 site in Colombia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Claudia Carvajal (+57-311-856-4991, crcarvajal@fon.org.co), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intraocular pressure (time frame: Six months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02679482, which also lists 18 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2016.